Arcturus Therapeutics Holdings Inc (NQ:ARCT)

13.35 -1.31 (-8.97%)

Delayed Quote Updated: 2:47 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why Arcturus Therapeutics Stock Is Skyrocketing Today ↗

November 02, 2022

Investors are applauding Arcturus' collaboration with CSL.

Via The Motley Fool

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? ↗

November 02, 2022

The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.

Via InvestorPlace

Where Arcturus Therapeutics Stands With Analysts ↗

November 02, 2022

Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines ↗

November 02, 2022

Via Benzinga

BARDA Backs Arcturus' Influenza Vaccine Program ↗

September 01, 2022

Via Benzinga

Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants ↗

August 18, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Arcturus Therapeutics ↗

November 02, 2022

Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings within the last quarter:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 02, 2022

Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.

Via Benzinga

Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket ↗

November 02, 2022

Gainers Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 02, 2022

Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday!

Via InvestorPlace

4 Analysts Have This to Say About Arcturus Therapeutics ↗

August 10, 2022

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:

Via Benzinga

Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 02, 2022

U.S. stock futures traded slightly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

November 01, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

October 26, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Recap: Arcturus Therapeutics Q2 Earnings ↗

August 09, 2022

Arcturus Therapeutics (NASDAQ:ARCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday ↗

September 30, 2022

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Arcturus Therapeutics to Attend the Following Investor Conferences

September 27, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

7 Small-Cap Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later ↗

September 22, 2022

With the market taking a dip and possibly poised to incur more red ink, these are the small-cap stocks to buy that appeal to contrarians.

Via InvestorPlace

Arcturus Therapeutics to Attend the Following Investor Conferences

September 01, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

August 31, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

August 18, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗

August 10, 2022

Via Benzinga

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

August 09, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

August 01, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

What 6 Analyst Ratings Have To Say About Arcturus Therapeutics ↗

July 19, 2022

Over the past 3 months, 6 analysts have published their opinion on Arcturus Therapeutics (NASDAQ:ARCT) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 21, 2022

From Arcturus Therapeutics Holdings Inc.

Via Business Wire

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

70 Stocks Moving In Monday's Mid-Day Session ↗

June 13, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.